Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACI 24

Drug Profile

ACI 24

Alternative Names: ACI-24; ACI-24.060; Anti-Abeta vaccine - AC immune; Pal1-15 acetate salt

Latest Information Update: 04 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AC Immune
  • Developer AC Immune; University of California, San Diego
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I/II Down syndrome

Most Recent Events

  • 28 Apr 2023 AC Immune plans to file an IND application to expand phase Ib/II ABATE clinical trial in USA, in H1 of 2023
  • 26 Jan 2023 Interim safety and immunogenicity data from a phase Ib/II trial in Alzheimer’s disease released by AC Immune
  • 04 Oct 2022 Phase-I/II clinical trials in Alzheimer's disease in Spain (unspecified route) (NCT05462106)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top